Study of REM-422 in Patients With AML or Higher Risk MDS

Prior treatment

• Has undergone hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of REM-422 or is receiving immunosuppressive therapy post HSCT at the time of screening, or has GVHD requiring systemic treatment (topical steroids for ongoing skin GVHD is permitted).
• Clinically significant active infection. Note: Patients with simple urinary tract infection or uncomplicated bacterial pharyngitis responding to active treatment are permitted. Note: Patients receiving intravenous (IV) antibiotics ≤ 7 days prior to enrollment are excluded (prophylactic antibiotics, antivirals, or antifungals are permitted).
• Current or expected need for daily systemic corticosteroid therapy ≥ 10 mg of prednisone equivalent.
  • Note: Patients who are receiving topical or inhaled corticosteroids with minimal systemic absorption are eligible for enrollment and may continue with minimal corticosteroid use as long as they are on a stable dose.
• Live vaccine ≤ 2 weeks prior to the start of REM-422.
• Use of moderate or strong cytochrome P450 (CYP)3A inhibitors (including azoles that are moderate to strong CYP3A inhibitors) or CYP3A inducers \< 5 half-lives or 14 days, whichever is shorter, prior to initiating REM-422 administration and during the study.
• Drugs that reduce gastric acidity, such as H2-receptor antagonists (eg, ranitidine, famotidine) and proton pump inhibitors (eg, omeprazole, esomeprazole) within 7 days prior to the initiation of REM-422 administration or during the study.
• Current use of prohibited medication ≤ 1 week before starting REM-422.
• Has undergone major surgery (opening a mesenchymal barrier such as the pleural cavity, peritoneum, or meninges or surgical procedures requiring general anesthesia) \< 4 weeks prior to enrollment.
• Radiation therapy ≤ 7 days prior to the start of REM-422.

Other illness

• Has immediate, life-threatening, severe complications of leukemia, such as uncontrolled bleeding, pneumonia with hypoxia or sepsis, and/or disseminated intravascular coagulation.
• Known hypersensitivity or contraindication to any component of REM-422 or to drugs chemically related to REM-422 or its excipients.
• Evidence of active HIV infection.
• Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
• Has dysphagia, short-gut syndrome, gastroparesis, or any other condition that limits the ingestion or gastrointestinal absorption of orally administered drugs.
• Clinically significant cardiovascular disease
• History of organ transplant that requires use of immunosuppressive agents.
• History or current autoimmune disease requiring systemic treatment (eg, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus).
• Any condition that, in the opinion of the Investigator, would interfere with evaluation of REM-422 or interpretation of the participant's safety or study results.

Age

• Concurrent or previous other malignancy ≤ 2 years of enrollment, except curatively treated malignancies including basal or squamous cell skin cancer, breast cancer, prostate intraepithelial neoplasm, and carcinoma in situ of the cervix.

Other

• Active central nervous system (CNS) leukemia or a confirmed diagnosis of CNS leukemia.
• Primary immunodeficiency.
• Currently pregnant, have intentions to become pregnant during the study duration, or are currently lactating.
• Unwillingness or inability to follow protocol requirements.

• Be able to provide informed consent.
• Be 18 or older at the time of informed consent.
• Disease criteria:
  • Histologically confirmed diagnosis of either:
  • R/R AML, defined as relapse after transplantation, second or later relapse, refractory to initial induction or reinduction treatment or to initial treatment with hypomethylating (HMA)-based combinations, relapse after initial treatment, or otherwise considered relapsed or refractory in the opinion of the Investigator.
  • High-risk and very-high-risk (VHR) MDS (higher-risk) per the International Prognostic Scoring System-Revised (IPSS-R) and/or International Prognostic Scoring System-Molecular (IPSS-M).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Has agreed to undergo serial blood and bone marrow sampling.
• Participants must have completed systemic non-investigational therapy at least 14 days prior to initiating REM-422. Hydroxyurea is permissible for controlling peripheral leukemic blasts prior to enrollment and for up to 28 days following initiation of REM-422.
• Toxicities from prior therapy must be either stable or recovered to ≤ Grade 1.
• Participants must be able to swallow and retain oral medications.
• Oxygen saturation \> 92% on room air or up to 2 L/min supplemental oxygen by nasal cannula with ≤ Grade 1 dyspnea.
• People of childbearing potential (POCBP) must have a negative serum beta-human chorionic gonadotropin test result.
• POCBP must agree to use acceptable, effective methods of contraception and not donate ova from screening until 6 months after discontinuation of REM-422. Women who have undergone surgical or ablative sterilization or who have been postmenopausal for ≥ 2 years are not considered to be of childbearing potential.
• Men must agree to use acceptable, effective methods of contraception and must agree not to donate sperm from the start of receiving REM-422 until 6 months after discontinuation of REM-422.
• Adequate organ function and laboratory parameters